144 related articles for article (PubMed ID: 19103722)
1. Tyrosine kinase inhibitors and modifications of thyroid function tests: a review.
Illouz F; Laboureau-Soares S; Dubois S; Rohmer V; Rodien P
Eur J Endocrinol; 2009 Mar; 160(3):331-6. PubMed ID: 19103722
[TBL] [Abstract][Full Text] [Related]
2. Risk Factors for New Hypothyroidism During Tyrosine Kinase Inhibitor Therapy in Advanced Nonthyroidal Cancer Patients.
Lechner MG; Vyas CM; Hamnvik OR; Alexander EK; Larsen PR; Choueiri TK; Angell TE
Thyroid; 2018 Apr; 28(4):437-444. PubMed ID: 29652599
[TBL] [Abstract][Full Text] [Related]
3. Tyrosine kinase inhibitors and immune checkpoint inhibitors-induced thyroid disorders.
Jannin A; Penel N; Ladsous M; Vantyghem MC; Do Cao C
Crit Rev Oncol Hematol; 2019 Sep; 141():23-35. PubMed ID: 31202955
[TBL] [Abstract][Full Text] [Related]
4. Tyrosine kinase inhibitor-induced hypothyroidism: mechanism and clinical implications.
Wang Z; Wang H; Bu C; Meng B; Mu Y; Gao S; Chen W; Tao X
Eur J Clin Pharmacol; 2024 Jun; 80(6):827-838. PubMed ID: 38483545
[TBL] [Abstract][Full Text] [Related]
5. Current evidence on thyroid related adverse events in patients treated with protein tyrosine kinase inhibitors.
Gabora K; Piciu A; Bădulescu IC; Larg MI; Stoian IA; Piciu D
Drug Metab Rev; 2019 Nov; 51(4):562-569. PubMed ID: 31718371
[TBL] [Abstract][Full Text] [Related]
6. Hypothyroidism During Tyrosine Kinase Inhibitor Therapy Is Associated with Longer Survival in Patients with Advanced Nonthyroidal Cancers.
Lechner MG; Vyas CM; Hamnvik OR; Alexander EK; Larsen PR; Choueiri TK; Angell TE
Thyroid; 2018 Apr; 28(4):445-453. PubMed ID: 29652597
[TBL] [Abstract][Full Text] [Related]
7. Association between new-onset hypothyroidism and clinical response in patients treated with tyrosine kinase inhibitor therapy in phase I clinical trials.
Bilen MA; Patel A; Hess KR; Munoz J; Busaidy NL; Wheler JJ; Janku F; Falchook GS; Hong DS; Meric-Bernstam F; Habra MA; Naing A
Cancer Chemother Pharmacol; 2016 Jul; 78(1):167-71. PubMed ID: 27286994
[TBL] [Abstract][Full Text] [Related]
8. The Combined Effect of Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors on Thyroid Function.
Tsai K; Ma H; Liang TZ; Xing Y; Chung S; Dorff T; Bell D; Lechner MG
Thyroid; 2024 Feb; 34(2):158-166. PubMed ID: 38069567
[No Abstract] [Full Text] [Related]
9. Expert opinion on thyroid complications of new anti-cancer therapies: Tyrosine kinase inhibitors.
Drui D; Illouz F; Do Cao C; Caron P
Ann Endocrinol (Paris); 2018 Oct; 79(5):569-573. PubMed ID: 30126626
[TBL] [Abstract][Full Text] [Related]
10. Thyroid dysfunction and tyrosine kinase inhibitors in renal cell carcinoma.
Bianchi L; Rossi L; Tomao F; Papa A; Zoratto F; Tomao S
Endocr Relat Cancer; 2013 Oct; 20(5):R233-45. PubMed ID: 23833016
[TBL] [Abstract][Full Text] [Related]
11. [Thyroid dysfunction in patients treated with tyrosine kinase inhibitors].
Przytulska J; Tupikowski K; Bednarek-Tupikowska G
Pol Merkur Lekarski; 2014 Jan; 36(211):42-4. PubMed ID: 24645578
[TBL] [Abstract][Full Text] [Related]
12. Effects of tyrosine kinase inhibitors on thyroid function and thyroid hormone metabolism.
Basolo A; Matrone A; Elisei R; Santini F
Semin Cancer Biol; 2022 Feb; 79():197-202. PubMed ID: 33476722
[TBL] [Abstract][Full Text] [Related]
13. Tyrosine kinase inhibitor-induced hypothyroidism: incidence, etiology, and management.
Brown RL
Target Oncol; 2011 Dec; 6(4):217-26. PubMed ID: 22101606
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms of TKI-induced diarrhea in cancer patients.
Bowen JM
Curr Opin Support Palliat Care; 2013 Jun; 7(2):162-7. PubMed ID: 23399616
[TBL] [Abstract][Full Text] [Related]
15. Thyroid dysfunctions induced by tyrosine kinase inhibitors.
Fallahi P; Ferrari SM; Vita R; Di Domenicantonio A; Corrado A; Benvenga S; Antonelli A
Expert Opin Drug Saf; 2014 Jun; 13(6):723-33. PubMed ID: 24821006
[TBL] [Abstract][Full Text] [Related]
16. Combined use of tyrosine kinase inhibitors with PD-(L)1 blockade increased the risk of thyroid dysfunction in PD-(L)1 blockade: a prospective study.
Kobayashi T; Iwama S; Yamagami A; Izuchi T; Suzuki K; Otake K; Yasuda Y; Ando M; Onoue T; Miyata T; Sugiyama M; Hagiwara D; Suga H; Banno R; Hase T; Nishio N; Mori S; Shimokata T; Sano T; Niimi K; Yoshikawa N; Akamatsu S; Ando Y; Akiyama M; Sone M; Ishii M; Arima H
Cancer Immunol Immunother; 2024 Jun; 73(8):146. PubMed ID: 38833157
[TBL] [Abstract][Full Text] [Related]
17. Frequency and Severity of Hypothyroidism During TKI Therapy in the Pediatric and Young Adult Population.
Segev N; Arora S; Khoury J; Yayah Jones NH; Chuang J
J Pediatr Hematol Oncol; 2022 Oct; 44(7):e964-e967. PubMed ID: 35973039
[TBL] [Abstract][Full Text] [Related]
18. Correlation of degree of hypothyroidism with survival outcomes in patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor receptor tyrosine kinase inhibitors.
Bailey EB; Tantravahi SK; Poole A; Agarwal AM; Straubhar AM; Batten JA; Patel SB; Wells CE; Stenehjem DD; Agarwal N
Clin Genitourin Cancer; 2015 Jun; 13(3):e131-7. PubMed ID: 25497584
[TBL] [Abstract][Full Text] [Related]
19. Endocrine side-effects of anti-cancer drugs: thyroid effects of tyrosine kinase inhibitors.
Illouz F; Braun D; Briet C; Schweizer U; Rodien P
Eur J Endocrinol; 2014 Sep; 171(3):R91-9. PubMed ID: 24833135
[TBL] [Abstract][Full Text] [Related]
20. Clinical pharmacokinetics of tyrosine kinase inhibitors: implications for therapeutic drug monitoring.
Josephs DH; Fisher DS; Spicer J; Flanagan RJ
Ther Drug Monit; 2013 Oct; 35(5):562-87. PubMed ID: 24052062
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
